Although a number of studies have indicated that amyloid deposition and tau proteins are two core neuropathologies responsible for AD, results of clinical trials that modulated these two pathological proteins by means of straightforward amyloid- or tau-immunotherapy were disappointing [12,13,14,15]. The gene discussed is MAPT; the disease is Alzheimer disease.